|1.||Witjes, J Alfred: 5 articles (06/2009 - 04/2005)|
|2.||Puri, Rajiv: 4 articles (06/2009 - 10/2006)|
|3.||Phillips, Roger M: 3 articles (01/2013 - 10/2006)|
|4.||Hendricksen, Kees: 3 articles (01/2012 - 09/2007)|
|5.||van der Heijden, Antoine G: 3 articles (06/2009 - 04/2005)|
|6.||Beijnen, Jos H: 3 articles (01/2007 - 10/2006)|
|7.||Phillips, R M: 2 articles (01/2014 - 10/2001)|
|8.||Witjes, J A: 2 articles (04/2012 - 07/2008)|
|9.||Hendricksen, K: 2 articles (04/2012 - 07/2008)|
|10.||Cornel, Erik B: 2 articles (06/2009 - 10/2006)|
|1.||Urinary Bladder Neoplasms (Bladder Cancer)
04/01/2012 - "We studied the safety and efficacy of multiple adjuvant apaziquone instillations in patients with high risk nonmuscle invasive bladder cancer. "
01/01/2012 - "The objective of this study was to assess antitumor activity and safety of 3 different formulations of intravesical apaziquone in an orthotopic rat bladder cancer model. "
01/01/2012 - "Apaziquone used intravesically showed significant activity in phase I and II marker lesion studies in non-muscle-invasive bladder cancer. "
06/01/2009 - "To study the time-to-recurrence and duration of response in non-muscle invasive bladder cancer (NMIBC) patients, with a complete ablative response after intravesical apaziquone instillations. "
06/01/2009 - "Two-year follow-up of the phase II marker lesion study of intravesical apaziquone for patients with non-muscle invasive bladder cancer."
01/01/2000 - "The aim of the present phase I study was to determine the toxicities and the maximal tolerated dose (MTD) of EO9 administered as a 5-min i.v. infusion weekly to patients with solid cancers. "
05/01/2009 - "Before apaziquone instillation, the mean +/- SE recurrence rate and tumor rate per year was 1.5 +/- 0.2 and 4.8 +/- 1.2, respectively, and these decreased to 0.6 +/- 0.25 and 1.5 +/- 0.8, respectively, after apaziquone treatment (P <0.05). "
10/01/2006 - "We studied the ablative activity of intravesical apaziquone (EOquin) on a papillary marker tumor and determined the incidence of side effects. "
01/01/2000 - "EO9 is a new synthetic bioreductive alkylating indoloquinone, with preferential activity against solid tumors and higher antitumor activity under anaerobic conditions compared with aerobic conditions. "
07/18/1997 - "Both compounds showed antitumor activity both as single agents and in combination with radiation, with some substantial improvements over EO9 (3) at maximum tolerated doses and as single agents against the RIF-1 tumor model and comparable efficacy in the KHT tumor model."
|3.||Mouth Neoplasms (Oral Cancer)
01/01/2015 - "Anticancer Activity of Apaziquone in Oral Cancer Cells and Xenograft Model: Implications for Oral Cancer Therapy."
01/01/2015 - "In conclusion, our in vitro and in vivo studies identified and demonstrated the pre-clinical efficacy of Apaziquone, as a potential novel anti-cancer therapeutic candidate for oral cancer management. "
01/01/2015 - "Apaziquone treated OSCC cells showed increased activation of Caspase 9 and Caspase 3, and Poly (ADP ribose) polymerase (PARP) cleavage suggesting induction of apoptosis by apaziquone in oral cancer cells. "
01/01/2012 - "The orthotopic Fischer/AY-27 rat bladder urothelial cell carcinoma model to test the efficacy of different apaziquone formulations."
02/01/2012 - "Apaziquone is a promising local agent for the treatment and prevention of recurrent urothelial carcinoma of the bladder. "
06/01/2009 - "Transurethral resection of bladder tumour(s) (TURBT) was performed in patients with multiple pTa-T1 G1-2 urothelial cell carcinoma (UCC) of the bladder, with the exception of one marker lesion of 0.5-1.0 cm. Intravesical apaziquone was administered at weekly intervals for six consecutive weeks, without maintenance instillations. "
07/01/1991 - "EO9 was also metabolized by QR from HT29 human colon carcinoma cells but rather less efficiently than by the rat tumor enzyme. "
01/01/1992 - "In addition, when the in vitro sensitivity of two human colon carcinoma cell lines was compared, EO9 was 15-30 fold more active in the DT-diaphorase rich HT29 line than in the enzyme-deficient BE cell line counterpart. "
05/15/1994 - "Relative importance of DT-diaphorase and hypoxia in the bioactivation of EO9 by human lung tumor cell lines."
01/01/1994 - "Hypoxia increased the cytotoxicity of cells containing low but not high levels of DT-diaphorase, implying that both 1- and 2-electron reductive activation processes can be important for expression of EO9 toxicity. "
01/01/1994 - "Factors affecting sensitivity to EO9 in rodent and human tumour cells in vitro: DT-diaphorase activity and hypoxia."
01/01/1997 - "These data are consistent with cytotoxicity studies that indicate that DT-diaphorase appears to be important in EO9 activation under aerobic conditions, but other enzymes may be more relevant under hypoxia. "
03/01/1998 - "5-substituted analogues of 3-hydroxymethyl-5-aziridinyl-1-methyl-2-[1H-indole-4,7-dione]prop-2-en- 1-ol (EO9, NSC 382459) and their regioisomers as hypoxia-selective agents: structure-cytotoxicity in vitro."
|1.||NAD(P)H Dehydrogenase (Quinone) (Quinone Reductase)
|4.||apaziquone (E 09)
|2.||Drug Therapy (Chemotherapy)
|3.||Heterologous Transplantation (Xenotransplantation)